Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pOTTC1329 - pAAV EF1a HA-hM4D(Gi) Citations (1)

Originally described in: Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA, Ellis RJ, Richie CT, Harvey BK, Dannals RF, Pomper MG, Bonci A, Michaelides M Science. 2017 Aug 4;357(6350):503-507. doi: 10.1126/science.aan2475.
PubMed Journal

Articles Citing pOTTC1329 - pAAV EF1a HA-hM4D(Gi)

Articles
High-potency ligands for DREADD imaging and activation in rodents and monkeys. Bonaventura J, Eldridge MAG, Hu F, Gomez JL, Sanchez-Soto M, Abramyan AM, Lam S, Boehm MA, Ruiz C, Farrell MR, Moreno A, Galal Faress IM, Andersen N, Lin JY, Moaddel R, Morris PJ, Shi L, Sibley DR, Mahler SV, Nabavi S, Pomper MG, Bonci A, Horti AG, Richmond BJ, Michaelides M. Nat Commun. 2019 Oct 11;10(1):4627. doi: 10.1038/s41467-019-12236-z. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.